Clinical Trials Logo
  1. Home
  2. Melanoma
  3. NCT03978611
  4. Details
NCT03978611 Clinical Trial

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Melanoma Clinical Trial

Official title:
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination With Ipilimumab or Ipilimumab Alone in Participants With Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03978611
Other study ID # CA224-083
Secondary ID 2019-000132-25
Status Completed
Phase Phase 1
First received
Last updated
Start date December 9, 2021
Est. completion date July 26, 2023

Study information
Verified date September 2023
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) of relatlimab in combination with ipilimumab.

Recruitment information / eligibility
Status Completed
Enrollment 11
Est. completion date July 26, 2023
Est. primary completion date July 26, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Must have documented progression while on a prior anti-programmed cell death protein 1 (PD-1) containing regimen limited to Nivolumab or Pembrolizumab - Must have histologically confirmed advanced unresectable (Stage III) or metastatic (Stage IV) melanoma, as per (AJCC) staging system - Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses - Eastern Cooperative Oncology Group (ECOG) 0-1 Exclusion Criteria: - History of uveal melanoma - Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome - Prior treatment with ipilimumab, relatlimab, or any other cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or lymphocyte-activation gene 3 (LAG-3) targeted agents

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Relatlimab
Specified dose on specified days
• Ipilimumab
Specified dose on specified days

Locations
Country Name City State
Belgium Local Institution - 0017 Antwerpen
Belgium Local Institution - 0016 Brussels
Belgium Local Institution - 0018 Bruxelles Brussels
Belgium Local Institution - 0038 Bruxelles
Canada Local Institution - 0044 Ottawa Ontario
Germany Local Institution - 0037 Erlangen
Germany Local Institution - 0034 Essen
Germany Local Institution - 0036 Gera
Germany Local Institution - 0035 Hannover
Germany Local Institution - 0033 Heidelberg
Germany Local Institution - 0032 Lübeck
Germany Local Institution - 0040 Nuremberg
Spain Local Institution - 0026 Barcelona
Spain Local Institution - 0030 Cordoba
Spain Local Institution - 0027 Hospitalet de Llobregat - Barcelona
Spain Local Institution - 0029 Madrid
Spain Local Institution - 0031 San Sebastian
Spain Local Institution - 0028 Valencia
United States Local Institution - 0003 Ann Arbor Michigan
United States Local Institution - 0004 Chicago Illinois
United States Local Institution - 0002 Los Angeles California
United States Local Institution - 0005 Los Angeles California
United States Local Institution - 0015 Miami Florida
United States Local Institution - 0008 Morristown New Jersey
United States Local Institution - 0001 Santa Monica California
United States Local Institution - 0023 Tucson Arizona

Sponsors (1)
Lead Sponsor Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  Germany,  Spain, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of Participants with Adverse Events (AEs) Up to Follow-up Period (100 days after 34 cycles [1 cycle is of 3 weeks])
Primary Number of Participants with Serious Adverse Events (SAEs) Up to Follow-up Period (100 days after 34 cycles [1 cycle is of 3 weeks])
Primary Number of Participants With Adverse Events Including Dose Limiting Toxicity Up to 28 days after last study drug dose (approximately up to 2 years)
Primary Number of Participants with AEs resulting in Discontinuation Up to end of study (approximately 2.4 years)
Primary Number of Participants with AEs resulting in Death Up to end of study (approximately 2.4 years)
Primary Number of Participants with AEs resulting in Laboratory Abnormalities Up to end of study (approximately 2.4 years)
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study

External Links